Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-04-05

FDA Approved: LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Exelan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Lamivudine and Zidovudine from Exelan Pharmaceuticals, confirming continued availability of this fixed-dose combinat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamivudine and Zidovudine (Lamivudine and Zidovudine)

Snippet

SUPPL AP for LAMIVUDINE AND ZIDOVUDINE (LAMIVUDINE AND ZIDOVUDINE)